查看購物車
  • English
封面
市場調查報告書
商品編碼
1912437

後生元成分市場：按來源、形態、應用和通路分類 - 全球預測（2026-2032年）

Postbiotics Raw Material Market by Source, Form, Application, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，益生元成分市場價值將達到 1.5972 億美元，到 2026 年將成長至 1.7663 億美元，到 2032 年將達到 3.0322 億美元，複合年成長率為 9.59%。

關鍵市場統計數據
基準年 2025 1.5972億美元
預計年份：2026年 1.7663億美元
預測年份 2032 3.0322億美元
複合年成長率 (%) 9.59%

本文簡要概述了後生元成分如何從實驗室概念發展成為用途廣泛、性能穩定的成分，並推動過程的配方策略。

後生元成分已迅速從學術研究發展成為多個行業配方師和製造商的必備原料。這些成分由去活化的微生物細胞、細胞碎片、代謝物和功能性萃取物組成，與活性益生菌和化學惰性益生元相比，具有獨特的生物學和功能性作用。隨著科學表徵和生產控制的不斷完善，後生元因其穩定性、安全性和在複雜配方中的多功能性而日益受到認可。這吸引了那些在不宜或不宜使用活性微生物的情況下尋求可預測性能的配方師的注意。

科學、製造和商業力量如何融合，重塑供應鏈動態，並重新定位後生元成分在高價值產品類型中的應用

後生元成分的市場格局正在經歷變革性變化，科學、生產和商業性因素的共同作用重新定義了機會和風險。在科學層面，對宿主-微生物相互作用和生物活性代謝物譜的更深入機制理解，使得針對特定功能性結果的標靶原料選擇成為可能。這促使配方師不再侷限於泛泛的健康宣稱，而是轉向能夠明確作用機制的特定應用場景。

評估2025年關稅對後生元成分價值鏈的策略性連鎖反應，包括對供應鏈韌性、採購決策和配方策略的影響

2025年美國關稅政策對後生元成分供應鏈產生了複雜的影響，需要企業進行策略調整，而非單純轉移成本。在供應方面，關稅壓力迫使配方師和原料採購者重新評估採購區域，並加強供應商選擇流程。在關稅導致某些進口成分的到岸成本上升的情況下，採購商正努力透過供應商多元化、發展本地製造夥伴關係以及加快技術轉移來降低貿易政策波動帶來的風險。

可操作的細分訊息，揭示了製劑形式、應用案例和通路如何共同決定技術需求和商業性機會。

詳細的市場區隔揭示了技術差異和商業性吸引力最大的領域，這些差異為產品開發和市場推廣策略的選擇提供了基礎。基於成分的市場研究分類包括雙歧桿菌、乳酸桿菌、酵母菌和鏈球菌，每種菌種在人類和動物應用歷史、代謝產物譜以及安全性和監管方面均存在差異，從而影響其應用領域。基於劑型的分類涵蓋膠囊、液體、粉末和片劑，其中液體進一步細分為水性配方和油性配方，粉末則細分為凍乾粉和噴霧乾燥粉。這些劑型層面的差異直接影響生產需求、儲存特性和給藥途徑的選擇，指南特定應用的篩選。

區域法規環境、生產能力和消費者偏好將如何獨特地塑造關鍵全球市場中後生元成分的商業策略

地理位置對後生元成分的供應鏈決策、監理應變和市場推廣策略有顯著影響。美洲地區成熟的營養保健品和機能性食品生產商對後生元成分的需求強勁，他們越來越重視轉化科學和線上直銷銷售管道，強調清晰的產品聲明和可追溯性。該地區還擁有大規模的契約製造，能夠支持將新成分快速整合到消費品中，並實現配方的快速最佳化。

深入了解原料生產商的差異化、技術投資和夥伴關係模式，將決定哪些公司將在配方師和商業客戶中獲得優先地位。

原料領域的競爭因素取決於菌株來源、製程控制、分析嚴謹性和商業性支援方面的差異。領先的原料供應商正投資於可驗證的品質系統、菌株表徵和可靠的分析證書，以滿足配方開發人員和受監管目標產品類別日益複雜的需求。供應商、契約製造和研究機構之間的策略聯盟正成為加速新產品上市和降低規模化生產風險的主要途徑。

為製造商和供應商提供切實可行的、優先排序的建議，以增強供應鏈韌性、加快產品開發並提高跨通路商業性可行性。

行業領導者應採取一系列協同措施，將科學進步和市場趨勢轉化為永續的競爭優勢。首先，透過對多家地理分散的供應商進行資格認證，並投資於技術轉移能力建設，增強供應鏈合格，從而在商業性可行的情況下實現本地化生產。其次，將研發投資與明確的應用需求相匹配，重點關注菌株特異性表徵、配方相容性以及可擴展的加工方法，例如可控去活化和先進乾燥技術。

對混合方法研究過程進行透明描述，結合技術檢驗、相關人員訪談和三角測量技術，以得出可操作且檢驗的研究結果。

本分析採用定性和定量相結合的研究方法，以確保獲得可靠且可操作的洞見。主要研究包括對原料研發人員、契約製造生產商、製劑研發人員和法規專家進行結構化訪談，以了解即時營運限制、證據要求和商業性優先事項。次要研究包括仔細審查科學文獻、專利申請和監管指南，檢驗作用機制聲明並繪製智慧財產權格局圖。

簡潔扼要的總結強調了整合技術檢驗、供應鏈韌性和有針對性的商業化對於抓住新機會的策略必要性。

綜合來看，這些洞見預示著未來後生元成分不再只是可互換的商品成分，而是能夠跨多個品類打造差異化產品策略的關鍵因素。菌株科學、製程控制和分析檢驗的進步，使供應商能夠提供清晰的功能性價值提案，滿足目標產品產品和消費品的需求；同時，不斷變化的貿易趨勢和分銷模式，也使得供應鏈韌性和監管準備成為企業競爭的重中之重。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 後生元成分市場（依來源分類）

  • 雙歧桿菌
  • 乳酸桿菌
  • 釀酒酵母
  • 鏈球菌

9. 後生元成分市場（依形式分類）

  • 膠囊
  • 液體
    • 水溶液
    • 油膩的
  • 粉末
    • 冷凍乾燥
    • 噴霧乾燥
  • 藥片

第10章 後生元成分市場（依應用領域分類）

  • 動物飼料
  • 化妝品
  • 營養補充品
  • 機能性食品
  • 製藥

第11章 後生元成分市場（依通路分類）

  • 直銷
  • 批發商
  • 電子商務
  • 零售藥房

第12章：各地區的後生元成分市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 後生元成分市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 各國後生元成分市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國後生元成分市場

第16章 中國後生元原料市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Archer Daniels Midland Company
  • BioGaia AB
  • Cargill, Incorporated
  • Chr. Hansen Holding A/S
  • Gnosis by Lesaffre SA
  • International Flavors & Fragrances Inc.
  • Kerry Group plc
  • Lallemand Inc.
  • Lesaffre SA
  • MCLS Europe BV
  • Morinaga Milk Industry Co., Ltd.
  • Novozymes A/S
  • Postbiotica Srl
  • Probiotical SpA
  • Sabinsa Corporation
Product Code: MRR-AE420CB139A1

The Postbiotics Raw Material Market was valued at USD 159.72 million in 2025 and is projected to grow to USD 176.63 million in 2026, with a CAGR of 9.59%, reaching USD 303.22 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 159.72 million
Estimated Year [2026] USD 176.63 million
Forecast Year [2032] USD 303.22 million
CAGR (%) 9.59%

Concise strategic overview of how postbiotic raw materials have evolved from laboratory concepts to versatile, stable ingredients driving cross-sector formulation strategies

Postbiotic raw materials have moved quickly from academic curiosity to essential inputs for formulators and manufacturers across multiple industries. These materials, consisting of inactivated microbial cells, cell fragments, metabolites, and functional extracts, deliver biological and functional benefits distinct from living probiotics and chemically inert prebiotics. As scientific characterization and manufacturing control improve, postbiotics are becoming valued for their stability, safety profile, and versatility in complex formulations. This has attracted attention from formulators seeking predictable performance where the use of live microorganisms is impractical or undesirable.

The contemporary landscape for these ingredients reflects deeper collaboration between microbiologists, process engineers, and regulatory scientists. Advances in strain selection, controlled inactivation techniques, and analytical methods for potency and purity have reduced technical barriers and enhanced reproducibility. At the same time, cross-sector interest-spanning dietary supplements, functional foods, cosmetics, pharmaceuticals, and animal feed-has broadened the set of performance attributes that developers prioritize, including immunomodulation, barrier support, and formulation compatibility. Together, these dynamics underscore why postbiotic raw materials warrant strategic attention from product developers and supply chain managers.

How converging scientific, manufacturing, and commercial forces are reshaping supply dynamics and repositioning postbiotic raw materials across high-value product categories

The postbiotic raw material landscape is experiencing transformative shifts driven by scientific, manufacturing, and commercial forces that collectively redefine opportunity and risk. At the scientific level, more rigorous mechanistic understanding of host-microbe interactions and of bioactive metabolite profiles has enabled selection of targeted materials for specific functional outcomes. This has prompted formulators to move beyond general wellness claims and toward targeted use cases where defined modes of action can be substantiated.

Manufacturing transformations are equally consequential: refinements in inactivation processes, improved downstream purification, and scalable drying methods have increased availability of technical-grade materials suitable for high-value applications. Commercially, shifts in consumer expectations and distribution dynamics are favoring stable, easy-to-dose ingredients that integrate cleanly into capsules, tablets, powders, liquids, and topical systems. These converging developments have sharpened competitive differentiation around strain lineage, process traceability, and analytical certification, elevating the importance of transparent sourcing and robust quality documentation.

Assessing the strategic ripple effects of 2025 tariff measures on supply resilience, sourcing decisions, and formulation strategies across the postbiotic ingredient value chain

United States tariff actions in 2025 have produced a complex set of consequences for the postbiotic raw material supply chain that require strategic adaptation rather than simple cost pass-through. On the supply side, tariff pressure has incentivized formulators and ingredient buyers to re-evaluate sourcing geographies and to intensify supplier qualification efforts. Where tariffs raise landed costs on specific imported components, purchasers have pursued supplier diversification, sought local manufacturing partnerships, and accelerated technical transfers to mitigate exposure to trade policy volatility.

Downstream implications have emerged across procurement planning, inventory strategies, and formulation choices. Some manufacturers have reformulated to favor ingredients that are more readily sourced within lower-tariff jurisdictions or that can be produced at scale domestically under existing regulatory frameworks. Distributors and channel partners have adjusted margin expectations and contractual terms to accommodate increased logistics complexity. At the same time, tariff-driven uncertainty has highlighted strategic vulnerabilities in single-source dependencies and has amplified the value of supplier transparency, backward traceability, and flexibility in lead times. In aggregate, the effect of tariff measures has been to accelerate structural changes in sourcing and to prioritize supply chain resilience as a core component of competitive strategy.

Actionable segmentation intelligence revealing how source selection, formulation format, application use case, and distribution pathway jointly determine technical needs and commercial opportunity

Detailed segmentation reveals where technical differentiation and commercial traction are most pronounced, and these distinctions inform product development and go-to-market choices. Based on Source, market study categorization includes Bifidobacterium, Lactobacillus, Saccharomyces, and Streptococcus, each presenting distinct histories of human and animal use, differing metabolite profiles, and unique safety and regulatory footprints that influence where they are preferred. Based on Form, the segmentation spans Capsule, Liquid, Powder, and Tablet formats, with Liquid further defined into Aqueous and Oil Based presentations and Powder further classified as Freeze Dried and Spray Dried; these form-level differences translate directly into manufacturing requirements, storage profiles, and route-of-administration considerations that inform selection for a given application.

Based on Application, the examined categories include Animal Feed, Cosmetics, Dietary Supplements, Functional Foods, and Pharmaceuticals, a distribution that reflects both established and emerging routes to market and sets diverse performance expectations for potency, purity, and regulatory substantiation. Based on Distribution Channel, the study looks across Direct Sales, Distributors, E Commerce, and Retail Pharmacy, highlighting how channel economics, regulatory oversight, and consumer purchase behavior shape packaging, product claims, and commercial support models. Recognizing how each dimension intersects with formulation science and regulatory constraints allows stakeholders to prioritize investments in R&D, quality systems, and channel-specific launch plans.

How regional regulatory environments, manufacturing capacity, and consumer preferences uniquely shape commercial strategies for postbiotic materials across major global markets

Geographic dynamics materially influence supply chain decisions, regulatory engagement, and route-to-market strategies for postbiotic raw materials. In the Americas, there is strong demand from established dietary supplement and functional food manufacturers, with a growing emphasis on translational science and on-line direct-to-consumer channels that reward clear claims and traceability. This region also contains substantial contract manufacturing capacity, which supports faster integration of new raw materials into consumer-facing products and enables rapid iteration of dosage forms.

In Europe, Middle East & Africa, regulatory rigor and diverse national frameworks require precise documentation and careful labeling strategies, while consumer interest in natural and clinically supported ingredients remains robust. The region's sophisticated cosmetics and pharmaceutical sectors create opportunities for specialized, highly characterized postbiotic ingredients. In Asia-Pacific, a combination of strong manufacturing ecosystems, active ingredient innovation, and rapidly evolving retail channels drives both scale manufacturing and novel application development. Across all regions, local regulatory expectations, intellectual property considerations, and logistics constraints inform where to locate production, how to structure partnerships, and what evidence base will best support commercialization.

Insights into supplier differentiation, technology investment, and partnership models that determine which companies secure preferred status with formulators and commercial customers

Competitive dynamics in the raw material segment are defined by differentiation in strain provenance, process control, analytical rigour, and commercial support. Leading ingredient providers are investing in demonstrable quality systems, strain characterization, and robust certificates of analysis to meet the increasingly exacting needs of formulators and regulated product categories. Strategic partnerships between suppliers, contract manufacturers, and research institutions are becoming a primary route to accelerate new product introductions and to de-risk scale-up challenges.

At the commercial level, firms that combine formulation support, flexible packaging, and reliable logistics are establishing preferred supplier status with brand owners. Investment in pilot-scale production, expanded drying capacities such as freeze-drying and spray-drying, and validated inactivation processes yield operational advantages during product launches. Additionally, companies that prioritize transparent supply chains, third-party testing, and regulatory engagement are better positioned to address both customer procurement demands and evolving compliance expectations in multiple end-use markets.

Practical and prioritized recommendations for manufacturers and suppliers to build supply resilience, accelerate product development, and strengthen commercial execution across channels

Industry leaders should pursue a set of coordinated actions to translate scientific progress and market signals into durable competitive advantage. First, strengthen supply chain resilience by qualifying multiple suppliers across geographies and by investing in technical transfer capabilities to enable local production where commercially warranted. Second, align R&D investments with defined application needs, focusing on strain-specific characterization, formulation compatibility, and scalable processing methods such as controlled inactivation and advanced drying techniques.

Third, deepen commercial support offerings through co-development, technical documentation packages, and channel-specific materials for direct sales, distributors, e-commerce platforms, and retail pharmacy partners. Fourth, engage proactively with regulatory bodies to clarify permissible claims and to expedite necessary registrations or notifications; robust regulatory engagement reduces time-to-market risk. Finally, embed sustainability and traceability practices into sourcing and manufacturing narratives to meet growing buyer and end-consumer expectations for provenance and environmental responsibility. Taken together, these actions will help companies convert technical capability into reliable market differentiation.

Transparent description of a mixed-methods research process combining technical validation, stakeholder interviews, and triangulation to produce actionable and verifiable insights

The research approach underpinning this analysis combined qualitative and quantitative qualitative techniques to ensure robust, actionable findings. Primary research included structured interviews with ingredient developers, contract manufacturers, formulators, and regulatory experts to capture real-time operational constraints, evidence needs, and commercial priorities. Secondary exploration of scientific literature, patent filings, and regulatory guidelines was used to validate mechanistic claims and to map intellectual property landscapes.

Analytical triangulation integrated laboratory method reviews, manufacturing process assessments, and supply chain mapping to surface where technical bottlenecks and sourcing risks exist. Validation steps included cross-checks with independent technical advisers and with procurement professionals to ensure that recommended actions are both technically feasible and commercially viable. This blend of technical validation, stakeholder interviews, and triangulated evidence provides a balanced foundation for the insights and recommendations presented here.

Concise concluding synthesis highlighting the strategic imperatives for integrating technical validation, supply resilience, and targeted commercialization to capture emerging opportunities

The collective evidence points to a future where postbiotic raw materials become differentiated components of multi-category product strategies rather than interchangeable commodity inputs. Advances in strain science, process control, and analytical verification are enabling suppliers to present clear functional value propositions that meet the needs of regulated and consumer-facing applications alike. Meanwhile, changing trade dynamics and distribution patterns are elevating supply chain resilience and regulatory preparedness as competitive priorities.

For stakeholders across the value chain, the imperative is clear: integrate technical certification and supply transparency into commercial narratives, diversify sourcing to mitigate trade and logistics risk, and invest in targeted R&D that maps directly to application-specific performance criteria. Organizations that adopt these priorities will be better positioned to capitalize on the growing demand for stable, well-characterized bioactive ingredients while minimizing exposure to policy and market disruptions.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Postbiotics Raw Material Market, by Source

  • 8.1. Bifidobacterium
  • 8.2. Lactobacillus
  • 8.3. Saccharomyces
  • 8.4. Streptococcus

9. Postbiotics Raw Material Market, by Form

  • 9.1. Capsule
  • 9.2. Liquid
    • 9.2.1. Aqueous
    • 9.2.2. Oil Based
  • 9.3. Powder
    • 9.3.1. Freeze Dried
    • 9.3.2. Spray Dried
  • 9.4. Tablet

10. Postbiotics Raw Material Market, by Application

  • 10.1. Animal Feed
  • 10.2. Cosmetics
  • 10.3. Dietary Supplements
  • 10.4. Functional Foods
  • 10.5. Pharmaceuticals

11. Postbiotics Raw Material Market, by Distribution Channel

  • 11.1. Direct Sales
  • 11.2. Distributors
  • 11.3. E Commerce
  • 11.4. Retail Pharmacy

12. Postbiotics Raw Material Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Postbiotics Raw Material Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Postbiotics Raw Material Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Postbiotics Raw Material Market

16. China Postbiotics Raw Material Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Archer Daniels Midland Company
  • 17.6. BioGaia AB
  • 17.7. Cargill, Incorporated
  • 17.8. Chr. Hansen Holding A/S
  • 17.9. Gnosis by Lesaffre S.A.
  • 17.10. International Flavors & Fragrances Inc.
  • 17.11. Kerry Group plc
  • 17.12. Lallemand Inc.
  • 17.13. Lesaffre S.A.
  • 17.14. MCLS Europe B.V.
  • 17.15. Morinaga Milk Industry Co., Ltd.
  • 17.16. Novozymes A/S
  • 17.17. Postbiotica S.r.l.
  • 17.18. Probiotical S.p.A.
  • 17.19. Sabinsa Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL POSTBIOTICS RAW MATERIAL MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY BIFIDOBACTERIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY BIFIDOBACTERIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY BIFIDOBACTERIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LACTOBACILLUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LACTOBACILLUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LACTOBACILLUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SACCHAROMYCES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SACCHAROMYCES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SACCHAROMYCES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY STREPTOCOCCUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY STREPTOCOCCUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY STREPTOCOCCUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY CAPSULE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY CAPSULE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY CAPSULE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY AQUEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY AQUEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY AQUEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY OIL BASED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY OIL BASED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY OIL BASED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FREEZE DRIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FREEZE DRIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FREEZE DRIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SPRAY DRIED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SPRAY DRIED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SPRAY DRIED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY TABLET, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY TABLET, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY TABLET, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY ANIMAL FEED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY ANIMAL FEED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY ANIMAL FEED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COSMETICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COSMETICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COSMETICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DIETARY SUPPLEMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DIETARY SUPPLEMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DIETARY SUPPLEMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FUNCTIONAL FOODS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FUNCTIONAL FOODS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FUNCTIONAL FOODS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY PHARMACEUTICALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY PHARMACEUTICALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY PHARMACEUTICALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DIRECT SALES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DIRECT SALES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY E COMMERCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY E COMMERCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY E COMMERCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 131. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 137. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 138. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 139. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 140. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 141. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 142. GCC POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 152. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 153. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 154. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 155. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 157. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 159. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 160. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 161. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 162. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 163. G7 POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 164. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 166. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 167. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 168. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 169. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 170. NATO POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 171. GLOBAL POSTBIOTICS RAW MATERIAL MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 173. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 174. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 175. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 176. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 177. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 178. UNITED STATES POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 180. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY SOURCE, 2018-2032 (USD MILLION)
  • TABLE 181. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY FORM, 2018-2032 (USD MILLION)
  • TABLE 182. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY LIQUID, 2018-2032 (USD MILLION)
  • TABLE 183. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY POWDER, 2018-2032 (USD MILLION)
  • TABLE 184. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 185. CHINA POSTBIOTICS RAW MATERIAL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)